2025
Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)
Klausen M, Kuzey T, Pedersen J, Justesen S, Rasmussen L, Knorr U, Mason G, Ekstrøm C, Holst J, Koob G, Benveniste H, Volkow N, Knudsen G, Vilsbøll T, Fink-Jensen A. Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial). BMJ Open 2025, 15: e086454. PMID: 39779270, PMCID: PMC11749217, DOI: 10.1136/bmjopen-2024-086454.Peer-Reviewed Original ResearchConceptsAlcohol use disorderUse disorderGamma-aminobutyric acidComorbid obesityAlcohol cue reactivityCognitive behavioral therapyHeavy drinking daysWhite matter tract integrityBrain gamma-aminobutyric acidGlucagon-like peptide-1Alcohol consumptionMental health disordersReduce alcohol consumptionClinical trialsCue reactivityPlacebo-controlled clinical trialBehavioral therapyDrinking daysFunctional connectivityGLP-1 receptor agonist semaglutideWeeks of treatmentDouble-blind clinical trialTract integrityEthics Committee of the Capital Region of DenmarkHealth disorders
2023
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboExamining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III
Fields L, Roberts W, Schwing I, McCoy M, Verplaetse T, Peltier M, Carretta R, Zakiniaeiz Y, Rosenheck R, McKee S. Examining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III. Drug And Alcohol Dependence Reports 2023, 7: 100162. PMID: 37159814, PMCID: PMC10163607, DOI: 10.1016/j.dadr.2023.100162.Peer-Reviewed Original ResearchTobacco use disorderSubstance use disordersBody mass indexUse disordersPsychiatric conditionsRisk of SUDAdditional substance use disordersSingle health conditionsRelated Conditions Wave IIIWorse health outcomesNational Epidemiological SurveyPsychiatric disorder diagnosisHarmful substance useDSM-5 criteriaConcurrent obesityComorbid obesityMass indexSUD diagnosisRisk factorsObesityComorbid diagnosesEpidemiological surveyHealth outcomesNESARC-IIIDisorder diagnosis
2020
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesity
2017
Rumination in Patients with Binge‐Eating Disorder and Obesity: Associations with Eating‐Disorder Psychopathology and Weight‐bias Internalization
Wang SB, Lydecker JA, Grilo CM. Rumination in Patients with Binge‐Eating Disorder and Obesity: Associations with Eating‐Disorder Psychopathology and Weight‐bias Internalization. European Eating Disorders Review 2017, 25: 98-103. PMID: 28078784, PMCID: PMC5318238, DOI: 10.1002/erv.2499.Peer-Reviewed Original ResearchConceptsShape/weightWeight bias internalizationEating-disorder psychopathologyBinge-eating disorderCognitive processesGreater eating-disorder psychopathologyImportant cognitive processesOvervaluation of shapeGreater weight bias internalizationHierarchical multiple regressionTreatment-seeking patientsGreater ruminationRuminationDiscrimination experiencesPhysical healthPsychopathologyNegative attitudesMultiple regressionOvervaluationObesity treatmentComorbid obesityAttitudesDisordersExperienceFindings
2016
Sex Differences and Correlates of Pain in Patients with Comorbid Obesity and Binge Eating Disorder
Masheb RM, White MA, Grilo CM. Sex Differences and Correlates of Pain in Patients with Comorbid Obesity and Binge Eating Disorder. European Eating Disorders Review 2016, 24: 247-250. PMID: 26841114, PMCID: PMC4821688, DOI: 10.1002/erv.2432.Peer-Reviewed Original ResearchConceptsCorrelates of painMetabolic risk factorsRisk factorsHigh-density lipoprotein cholesterolObesity-related health risksBrief Pain InventoryPresence of painGreater pain severitySample of patientsSex differencesTreatment-seeking patientsComorbid obesityLipoprotein cholesterolPain severityPain InventoryComorbid painPain interferenceMore painPainMetabolic markersBinge frequencyAnalysis of covarianceComorbid bingeClinical implicationsPatients
2007
A pilot study of a weight management program with food provision in schizophrenia
Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, Brownell KD, Wexler BE. A pilot study of a weight management program with food provision in schizophrenia. Schizophrenia Research 2007, 96: 198-205. PMID: 17628437, DOI: 10.1016/j.schres.2007.05.022.Peer-Reviewed Original ResearchConceptsWeight lossSignificant medical risksMeaningful weight lossWeight loss programWeight management programSevere mental illnessSerious medical problemLifestyle modificationComorbid obesityLoss programPilot trialGeneral populationMetabolic indicesCognitive impairmentMental illnessMedical riskMedical problemsWeight gainObesityPilot studySpecific populationsSchizophreniaBehavioral programHealthy foodsReplacement program
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply